Fan Z H, Ren F
Beijing Youan Hospital, Capital Medical University Beijing Institute of Heputology, Beijing 100069, China.
Zhonghua Gan Zang Bing Za Zhi. 2022 Dec 20;30(12):1382-1386. doi: 10.3760/cma.j.cn501113-20200419-00197.
Hepatocellular carcinoma (HCC) is one of the common malignant tumors. However, the detection of biomarkers can't meet the clinical needs for the diagnosis and prognosis of HCC now. Circulating tumor DNA (ctDNA) is a highly tumor-specific DNA molecule that exists in the blood circulation. It is part of Circulating cell free DNA (cfDNA) and originates from the primary tumor or metastasis of cancer patients. Now, with the developing of next-generation sequencing technology and a full understanding of HCC genetics or epigenetic changes, we can analyze ctDNA mutations and methylation more comprehensively. Through continuous exploration of ctDNA mutations and methylation and continuous innovation of detection methods, HCC diagnosis and prognosis can be greatly improved in terms of specificity and sensitivity.
肝细胞癌（HCC）是常见的恶性肿瘤之一。然而，目前生物标志物的检测尚不能满足HCC诊断和预后的临床需求。循环肿瘤DNA（ctDNA）是一种存在于血液循环中的高度肿瘤特异性DNA分子。它是循环游离DNA（cfDNA）的一部分，源自癌症患者的原发性肿瘤或转移灶。如今，随着下一代测序技术的发展以及对HCC遗传学或表观遗传学变化的全面了解，我们能够更全面地分析ctDNA突变和甲基化。通过对ctDNA突变和甲基化的不断探索以及检测方法的持续创新，HCC诊断和预后在特异性和敏感性方面可得到极大改善。
